Replacing the defective CFTR gene in the lungs of patients with CF has proven problematic. The viral vectors have triggered unacceptable levels of host inflammatory responses in CF patients and additionally have low levels of gene transfer and efficacy. A clinical trial is currently underway in the UK employing a nonviral vector for gene transfer.12
